With the increase in carbapenem-resistant A. baumannii (CRAB) infections, there has been
a resurgence in the use of polymyxins, specifically colistin (COL). Since the reintroduction of …

Polymyxins are often last-line therapeutic agents used to treat infections caused by
multidrug-resistant A. baumannii. Recent reports of polymyxin-resistant A. baumannii …

Background Although polymyxin has been used as a last-resort antibiotic against resistant
bacteria, its use is restricted due to nephrotoxicity and neurotoxicity. While the present …

Acinetobacter baumannii has emerged as a pressing challenge in clinical practice, mainly
due to the development of resistance to multiple antibiotics, including colistin, one of the last …

The emergence of multidrug resistance among Acinetobacter baumannii is leading to an
increasing dependence on the use of polymyxins as last-hope antibiotics. Here, we utilized …

The global emergence of colistin resistance in carbapenem-resistant Acinetobacter
baumannii (CRAB) clinical isolates is a serious public health concern. We therefore aimed to …

Aims: Polymyxin-based combination therapy is often used to treat carbapenem-resistant
Acinetobacter baumannii (A. baumannii) infections. Although sulbactam is intrinsically active …

Administering polymyxin antibiotics in a traditional fashion may be ineffective against Gram-
negative ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae …

Objective To review recent clinical pharmacokinetic and pharmacodynamic data to optimize
dosing regimens for polymyxin B and colistin for treatment of infections due to A. baumannii …

Objectives: The emergence of polymyxin resistance threatens to leave clinicians with few
options for combatting drug-resistant Acinetobacter baumannii. The objectives of the current …